Vertex Pharmaceuticals forward PE VRTX

Share price divided by analysts' consensus earnings for the next twelve months, since 2011.

Today, Oct 23, 2026: 27.0×
10-year median: 26.4×
Against its 10-year history: 55th; percentile: 0 is its lowest day, 100 its highest
10-year range: 13.1× to 86.3×
Peer median: 26.7×

Vertex Pharmaceuticals' forward PE is 27.0× as of Oct 23, 2026.

That is above its ten-year median of 26.4×, close to the middle of its last ten years.

Over that time it ranged from 13.1× in Nov 2021 to 86.3× in Jul 2017.

The median for 8 biotech stocks of a similar size is 26.7×.

Forward PE over time

median 26.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	27.0×	22.6×	28.4×
2025	24.5×	19.6×	27.6×
2024	23.8×	23.1×	30.1×
2023	22.2×	19.3×	22.9×
2022	20.1×	15.9×	22.4×
2021	15.8×	13.1×	21.8×
2020	21.7×	19.1×	31.4×
2019	29.4×	26.4×	45.5×
2018	37.7×	36.6×	58.1×
2017	51.5×	48.4×	86.3×
2016	57.6×	57.6×	135×
2015	153×	142×	405×
2014	n/m a value too high to mean anything
2013	n/m a value too high to mean anything
2012	107×	16.2×	141×
2011	15.8×	12.7×	70.1×

Against its peers

Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.

Company	Forward PE
VRTXVertex Pharmaceuticals	27.0×
REGNRegeneron Pharmaceuticals	12.6×
ONCBeOne Medicines	48.1×
ALNYAlnylam Pharmaceuticals	26.7×
UTHRUnited Therapeutics	22.0×
INCYIncyte	49.5×
EXELExelixis	n/m
NBIXNeurocrine Biosciences	n/m
HALOHalozyme Therapeutics	n/m
Peer median	26.7×

Where Vertex Pharmaceuticals ranks

#39of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Vertex Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.